MPM Bioimpact LLC lessened its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,442,783 shares of the company's stock after selling 125,113 shares during the period. Compass Therapeutics makes up about 2.8% of MPM Bioimpact LLC's portfolio, making the stock its 14th biggest position. MPM Bioimpact LLC owned approximately 6.11% of Compass Therapeutics worth $16,041,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently bought and sold shares of the company. Vontobel Holding Ltd. purchased a new stake in Compass Therapeutics during the 1st quarter worth approximately $57,000. Squarepoint Ops LLC purchased a new stake in Compass Therapeutics during the 4th quarter worth approximately $35,000. Price T Rowe Associates Inc. MD lifted its stake in Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after acquiring an additional 11,326 shares during the period. Renaissance Technologies LLC lifted its stake in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock valued at $404,000 after acquiring an additional 56,000 shares during the period. Finally, ProShare Advisors LLC lifted its stake in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares during the period. Hedge funds and other institutional investors own 68.43% of the company's stock.
Compass Therapeutics Stock Performance
Shares of CMPX traded up $0.07 during trading hours on Friday, hitting $3.44. The stock had a trading volume of 388,871 shares, compared to its average volume of 1,386,189. The firm has a 50-day moving average price of $3.01 and a 200 day moving average price of $2.47. Compass Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $4.08. The firm has a market capitalization of $475.68 million, a price-to-earnings ratio of -7.64 and a beta of 1.50.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.
Wall Street Analyst Weigh In
CMPX has been the subject of several research reports. D. Boral Capital restated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Guggenheim lifted their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. Finally, Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a research note on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics has a consensus rating of "Buy" and an average price target of $12.89.
Check Out Our Latest Analysis on CMPX
About Compass Therapeutics
(
Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Articles
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
